American Bio Medica Corporation (ABMC)
USD 0.0
(9900.0%)
USD 0.0
(9900.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 2.2 Million USD | 50.48% |
| 2021 | 1.46 Million USD | -17.64% |
| 2020 | 1.78 Million USD | 13.74% |
| 2019 | 1.56 Million USD | 10.6% |
| 2018 | 1.41 Million USD | 11.51% |
| 2017 | 1.26 Million USD | -3.2% |
| 2016 | 1.31 Million USD | -20.01% |
| 2015 | 1.63 Million USD | -10.04% |
| 2014 | 1.82 Million USD | 16.27% |
| 2013 | 1.56 Million USD | -4.22% |
| 2012 | 1.63 Million USD | -8.3% |
| 2011 | 1.78 Million USD | -18.54% |
| 2010 | 2.19 Million USD | 6.21% |
| 2009 | 2.06 Million USD | -1.72% |
| 2008 | 2.09 Million USD | 29.91% |
| 2007 | 1.61 Million USD | 420.97% |
| 2006 | 310 Thousand USD | 61.46% |
| 2005 | 192 Thousand USD | 181.7% |
| 2004 | -235 Thousand USD | -23.04% |
| 2003 | -191 Thousand USD | -130.51% |
| 2002 | 626 Thousand USD | 35.79% |
| 2001 | 461 Thousand USD | 144.54% |
| 2000 | -1.03 Million USD | -2090.38% |
| 1999 | 52 Thousand USD | 101.63% |
| 1998 | -3.2 Million USD | -81.56% |
| 1997 | -1.76 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 107 Thousand USD | -95.15% |
| 2023 Q2 | - USD | -100.0% |
| 2022 FY | 2.2 Million USD | 50.48% |
| 2022 Q1 | 1.47 Million USD | 0.27% |
| 2022 Q2 | 1.53 Million USD | 4.08% |
| 2022 Q3 | 1.6 Million USD | 4.9% |
| 2022 Q4 | 2.2 Million USD | 37.45% |
| 2021 FY | 1.46 Million USD | -17.64% |
| 2021 Q1 | 1.86 Million USD | 5.0% |
| 2021 Q2 | 1.93 Million USD | 3.53% |
| 2021 Q3 | 1.74 Million USD | -9.97% |
| 2021 Q4 | 1.46 Million USD | -15.84% |
| 2020 Q4 | 1.78 Million USD | 5.89% |
| 2020 FY | 1.78 Million USD | 13.74% |
| 2020 Q2 | 1.54 Million USD | 60.33% |
| 2020 Q3 | 1.68 Million USD | 8.87% |
| 2020 Q1 | 963 Thousand USD | -38.47% |
| 2019 Q2 | 1.34 Million USD | -3.3% |
| 2019 FY | 1.56 Million USD | 10.6% |
| 2019 Q1 | 1.39 Million USD | -1.63% |
| 2019 Q4 | 1.56 Million USD | 3.1% |
| 2019 Q3 | 1.51 Million USD | 12.78% |
| 2018 Q1 | 1.34 Million USD | 5.67% |
| 2018 Q3 | 1.53 Million USD | 2.95% |
| 2018 Q2 | 1.49 Million USD | 11.11% |
| 2018 Q4 | 1.41 Million USD | -7.76% |
| 2018 FY | 1.41 Million USD | 11.51% |
| 2017 Q4 | 1.26 Million USD | 0.32% |
| 2017 Q1 | 1.39 Million USD | 6.03% |
| 2017 Q3 | 1.26 Million USD | -0.24% |
| 2017 FY | 1.26 Million USD | -3.2% |
| 2017 Q2 | 1.26 Million USD | -8.78% |
| 2016 Q1 | 1.28 Million USD | -21.78% |
| 2016 Q3 | 1.32 Million USD | 1.85% |
| 2016 Q4 | 1.31 Million USD | -0.68% |
| 2016 FY | 1.31 Million USD | -20.01% |
| 2016 Q2 | 1.29 Million USD | 1.09% |
| 2015 FY | 1.63 Million USD | -10.04% |
| 2015 Q4 | 1.63 Million USD | -4.49% |
| 2015 Q1 | 1.44 Million USD | -20.64% |
| 2015 Q2 | 1.63 Million USD | 13.21% |
| 2015 Q3 | 1.71 Million USD | 4.83% |
| 2014 Q1 | 1.55 Million USD | -0.89% |
| 2014 FY | 1.82 Million USD | 16.27% |
| 2014 Q2 | 1.46 Million USD | -5.67% |
| 2014 Q3 | 1.64 Million USD | 12.42% |
| 2014 Q4 | 1.82 Million USD | 10.63% |
| 2013 FY | 1.56 Million USD | -4.22% |
| 2013 Q1 | 2.52 Million USD | 54.22% |
| 2013 Q2 | 2.84 Million USD | 12.8% |
| 2013 Q3 | 2.08 Million USD | -26.63% |
| 2013 Q4 | 1.56 Million USD | -24.95% |
| 2012 FY | 1.63 Million USD | -8.3% |
| 2012 Q1 | 1.96 Million USD | 10.15% |
| 2012 Q3 | 1.98 Million USD | 11.45% |
| 2012 Q2 | 1.78 Million USD | -9.31% |
| 2012 Q4 | 1.63 Million USD | -17.62% |
| 2011 Q4 | 1.78 Million USD | -11.51% |
| 2011 FY | 1.78 Million USD | -18.54% |
| 2011 Q3 | 2.01 Million USD | -3.82% |
| 2011 Q2 | 2.09 Million USD | -7.17% |
| 2011 Q1 | 2.25 Million USD | 3.11% |
| 2010 Q2 | 2.19 Million USD | -13.66% |
| 2010 Q3 | 2.44 Million USD | 11.4% |
| 2010 Q1 | 2.54 Million USD | 23.18% |
| 2010 Q4 | 2.19 Million USD | -10.36% |
| 2010 FY | 2.19 Million USD | 6.21% |
| 2009 Q4 | 2.06 Million USD | -9.76% |
| 2009 Q1 | 1.86 Million USD | -11.11% |
| 2009 Q2 | 1.78 Million USD | -4.45% |
| 2009 Q3 | 2.28 Million USD | 28.23% |
| 2009 FY | 2.06 Million USD | -1.72% |
| 2008 FY | 2.09 Million USD | 29.91% |
| 2008 Q3 | 1.91 Million USD | 16.68% |
| 2008 Q1 | 1.54 Million USD | -4.4% |
| 2008 Q4 | 2.09 Million USD | 9.44% |
| 2008 Q2 | 1.64 Million USD | 6.41% |
| 2007 Q2 | 1.65 Million USD | 19.74% |
| 2007 Q4 | 1.61 Million USD | -4.04% |
| 2007 FY | 1.61 Million USD | 420.97% |
| 2007 Q1 | 1.38 Million USD | 346.13% |
| 2007 Q3 | 1.68 Million USD | 1.63% |
| 2006 Q2 | 244 Thousand USD | -45.29% |
| 2006 Q1 | 446 Thousand USD | 132.29% |
| 2006 Q3 | -205 Thousand USD | -184.02% |
| 2006 Q4 | 310 Thousand USD | 251.22% |
| 2006 FY | 310 Thousand USD | 61.46% |
| 2005 Q2 | 321 Thousand USD | -24.11% |
| 2005 FY | 192 Thousand USD | 181.7% |
| 2005 Q4 | 192 Thousand USD | 611.11% |
| 2005 Q1 | 423 Thousand USD | 280.0% |
| 2005 Q3 | 27 Thousand USD | -91.59% |
| 2004 Q2 | -416 Thousand USD | -77.78% |
| 2004 Q1 | -234 Thousand USD | -22.51% |
| 2004 Q3 | -346 Thousand USD | 16.83% |
| 2004 Q4 | -235 Thousand USD | 32.08% |
| 2004 FY | -235 Thousand USD | -23.04% |
| 2003 FY | -191 Thousand USD | -130.51% |
| 2003 Q1 | 576 Thousand USD | -7.99% |
| 2003 Q3 | 375 Thousand USD | -45.1% |
| 2003 Q4 | -191 Thousand USD | -150.93% |
| 2003 Q2 | 683 Thousand USD | 18.58% |
| 2002 FY | 626 Thousand USD | 35.79% |
| 2002 Q2 | 260 Thousand USD | -56.74% |
| 2002 Q4 | 626 Thousand USD | 83.58% |
| 2002 Q1 | 601 Thousand USD | 0.0% |
| 2002 Q3 | 341 Thousand USD | 31.15% |
| 2001 Q2 | -149 Thousand USD | 31.96% |
| 2001 Q3 | -805 Thousand USD | -440.27% |
| 2001 Q1 | -219 Thousand USD | 23.16% |
| 2001 FY | 461 Thousand USD | 144.54% |
| 2000 Q1 | -1.03 Million USD | -839.29% |
| 2000 Q3 | -93 Thousand USD | 84.13% |
| 2000 Q2 | -586 Thousand USD | 43.38% |
| 2000 FY | -1.03 Million USD | -2090.38% |
| 2000 Q4 | -285 Thousand USD | -206.45% |
| 1999 Q3 | 121 Thousand USD | -15.97% |
| 1999 Q2 | 144 Thousand USD | 176.92% |
| 1999 Q1 | 52 Thousand USD | 104.44% |
| 1999 FY | 52 Thousand USD | 101.63% |
| 1999 Q4 | 140 Thousand USD | 15.7% |
| 1998 Q4 | -1.17 Million USD | 26.61% |
| 1998 Q3 | -1.59 Million USD | 23.55% |
| 1998 Q2 | -2.08 Million USD | 34.72% |
| 1998 Q1 | -3.2 Million USD | -966.67% |
| 1998 FY | -3.2 Million USD | -81.56% |
| 1997 FY | -1.76 Million USD | 0.0% |
| 1997 Q4 | -300 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arrayit Corporation | 1.05 Million USD | -108.985% |
| Atlantic International Corp. | 236.49 Thousand USD | -832.785% |
| Biocept, Inc. | -788 Thousand USD | 379.949% |
| Bioqual, Inc. | -12 Million USD | 118.372% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -9601.394% |
| DermTech, Inc. | 17.65 Million USD | 87.504% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 100.385% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 129.904% |
| iMD Companies, Inc. | 1.11 Million USD | -97.685% |
| IDenta Corp. | 524.85 Thousand USD | -320.309% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 71.328% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 8284.921% |
| InVitro International | -313.14 Thousand USD | 804.473% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | -40.876% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 309496.914% |
| Medical Imaging Corp. | 3.79 Million USD | 41.809% |
| NovelStem International Corp. | 3.52 Million USD | 37.357% |
| Optigenex Inc. | 8.93 Million USD | 75.308% |
| PharmChem, Inc. | -1.49 Million USD | 247.616% |
| Proteome Sciences plc | 14.57 Million USD | 84.863% |
| Response Genetics, Inc | -13.08 Million USD | 116.858% |
| Rennova Health, Inc. | 14.82 Million USD | 85.125% |
| RushNet, Inc. | 4.8 Million USD | 54.05% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -1526.976% |
| Stella Diagnostics Inc. | 6.19 Million USD | 64.379% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | -23.627% |
| Todos Medical Ltd. | 38.31 Million USD | 94.242% |